These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31337618)

  • 1. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
    Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
    Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
    Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW
    Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
    Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
    Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase inhibition sensitizes cells to CDK4 blockade.
    Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE
    PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of APC-mutant colorectal cancer cells requires interaction between tankyrase and a thiol peroxidase, peroxiredoxin II.
    Kang DH; Lee JHS; Kang SW
    BMB Rep; 2017 Aug; 50(8):391-392. PubMed ID: 28683851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
    Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
    Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
    Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
    Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/Wingless Pathway Activation Is Promoted by a Critical Threshold of Axin Maintained by the Tumor Suppressor APC and the ADP-Ribose Polymerase Tankyrase.
    Wang Z; Tacchelly-Benites O; Yang E; Thorne CA; Nojima H; Lee E; Ahmed Y
    Genetics; 2016 May; 203(1):269-81. PubMed ID: 26975665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.
    Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW
    Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4.
    Prossomariti A; Piazzi G; D'Angelo L; Miccoli S; Turchetti D; Alquati C; Montagna C; Bazzoli F; Ricciardiello L
    Mol Cancer Res; 2018 Dec; 16(12):1965-1976. PubMed ID: 30072583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.